ProCE Banner Activity

Overview of Current and Emerging Treatment Options for Multiple Myeloma

Slideset Download

Download this slideset for a comprehensive overview of data supporting current and emerging treatment options for multiple myeloma across various settings.

Released: November 28, 2022

Expiration: November 27, 2023

Begin Activity

Share

Faculty

Shaji K. Kumar

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Bristol Myers Squibb

GlaxoSmithKline

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Regeneron Pharmaceuticals, Inc.

Partners

Smart Patients

ProCE Banner

Faculty Disclosure

Primary Author

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Shaji K. Kumar, MD: consultant/advisor (paid to institution): K36, AbbVie, Amgen, Antengene, ArcellX, AstraZeneca, BeiGene, Bluebird Bio, Bristol-Myers Squibb, Janssen, Loxo Oncology, Oncopeptides, Roche/Genentech, Sanofi; consultant/advisor: Secura Biotherapeutics, Takeda, Trillium; researcher (paid to institution): AbbVie, Allogene, Amgen, AstraZeneca, Bristol-Myers Squibb, Carsgen, GlaxoSmithKline, Janssen, Novartis, Roche/Genentech, Regeneron, Takeda.